Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03307564 · ClinicalTrials.gov registry record · NA
Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer
A NA study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- NA
- Development phase
- 6
- Enrollment target
NCT03307564 is a NA study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 6 participants.
The verdict
NCT03307564, a NA study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- NA
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this pilot imaging study is to evaluate the visibility of marking the interface between the pancreas and duodenum with TraceIT Tissue Marker. Patients with a pathologically confirmed diagnosis of BR/LAPC (borderline resectable/locally advanced pancreatic cancer) pancreatic adenocarcinomas indicated for neo-adjuvant image-guided radiotherapy with SBRT (stereotactic body radiation therapy) will be enrolled. This study will thus set the stage for further investigations using the TraceIT Tissue Marker to avoid duodenum toxicity with imaging localization, enabling further dose intensification with SBRT or IMRT to improve the clinical outcomes in BR/LAPC.
Interventions
- DEVICE TraceIT tissue marker injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2018-06-06 |
| Est. Completion | 2022-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03307564
The ClinicalTrials.gov registry entry for NCT03307564 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TraceIT tissue marker injection is the first listed.
NCT03307564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03307564 about?
NCT03307564 is a clinical study titled "Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer". The goal of this pilot imaging study is to evaluate the visibility of marking the interface between the pancreas and duodenum with TraceIT Tissue Marker. Patients with a pathologically confirmed diagnosis of BR/LAPC (borderline resectable/locally advanced pancreatic cancer) pancreatic adenocarcinoma...
What is the current status of trial NCT03307564?
This trial is currently completed. It is a NA study. The enrollment target is 6 participants. The study started on 2018-06-06. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03307564?
The interventions under investigation include: TraceIT tissue marker injection (DEVICE).
Who is sponsoring clinical trial NCT03307564?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.